You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

161 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
    prednisone
Jul 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB Limited Use
    fludarabine - For second-line therapy of patients with CLL who have failed or are intolerant to chlorambucil (tablets)
ODB - General Benefit
    cyclophosphamide - oral tablets
Jun 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Jun 2019
Drug
Other Name(s): Vesanoid®
Jun 2019
Drug
Other Name(s): Busulfex® , Myleran®
Jun 2019
Drug
Other Name(s): Alkeran®
Jun 2019
Drug
Other Name(s): MabCampath®
Sep 2019
Drug
Other Name(s): Thalomid®
Jun 2019
Drug
Other Name(s): Lanvis®
Jun 2019
Drug
Other Name(s): Lysodren®
Jun 2019
Drug
Other Name(s): Zolinza®
Jun 2019

Pages